Valuation: Evofem Biosciences, Inc.

Market Cap 1.06M 927K 857K 786K 1.49M 102M 1.51M 10.22M 4.02M 49.89M 3.98M 3.89M 172M P/E 2024
-0.08x
P/E 2025 26.7x
Enterprise Value 55.48M 48.49M 44.85M 41.15M 77.89M 5.35B 79.24M 535M 210M 2.61B 208M 204M 9.01B EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day-6.25%
1 week-20.21%
Current month-6.25%
1 month+7.14%
3 months-15.73%
6 months-19.35%
Current year-21.05%
1 week 0.01
Extreme 0.0075
0.01
1 month 0.01
Extreme 0.0072
0.01
Current year 0
Extreme 0.0008
0.01
1 year 0
Extreme 0.0008
0.02
3 years 0
Extreme 0.0008
0.82
5 years 0
Extreme 0.0008
1,865.62
10 years 0
Extreme 0.0008
23,549.99
Manager TitleAgeSince
Chief Executive Officer 57 31/12/2017
Director of Finance/CFO 49 12/04/2023
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 31/12/2017
Director/Board Member 58 31/12/2017
Date Insider Type Main position Quantity % Market Cap.
12/01/24 Sell

Chief Financial Officer

104 0.0010%
21/12/23 Sell

Director

10 0.0001%
13/04/23 Other

Chief Financial Officer

13,000 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
-6.25%-20.21%-23.47%-98.82% 1.06M
+1.50%-3.94%+48.02%+161.45% 1,031B
+1.08%-3.36%+51.95%+57.41% 595B
+3.94%+1.34%+32.89%+87.84% 431B
+0.42%-1.16%+29.43%+23.64% 326B
+1.03%-0.84%+29.58%+45.15% 277B
+0.49%-5.44%+21.00%+23.80% 263B
+1.59%+4.89%-22.56%-37.35% 224B
+3.81%+1.56%+23.50%+62.08% 193B
+3.41%+0.63%+23.53%+75.14% 164B
Average +1.00%-4.95%+21.39%+40.03% 350.43B
Weighted average by Cap. +1.64%-4.31%+34.61%+80.17%

Financials

2024 2025
Net sales 19.36M 16.93M 15.65M 14.36M 27.18M 1.87B 27.66M 187M 73.33M 911M 72.72M 71.12M 3.15B 20.18M 17.64M 16.32M 14.97M 28.34M 1.94B 28.83M 195M 76.44M 950M 75.8M 74.13M 3.28B
Net income -8.86M -7.74M -7.16M -6.57M -12.44M -854M -12.65M -85.41M -33.55M -417M -33.27M -32.54M -1.44B 391K 342K 316K 290K 549K 37.68M 558K 3.77M 1.48M 18.4M 1.47M 1.44M 63.52M
Net Debt 45.84M 40.07M 37.06M 34M 64.36M 4.42B 65.47M 442M 174M 2.16B 172M 168M 7.45B 54.42M 47.57M 43.99M 40.37M 76.4M 5.24B 77.72M 525M 206M 2.56B 204M 200M 8.84B
Logo Evofem Biosciences, Inc.
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
29
Date Price Change Volume
16/07/26 US$0.007500 -6.25% 266,101
15/07/26 US$0.008000 -3.61% 7,780
14/07/26 US$0.008300 -1.07% 241,142
13/07/26 US$0.008390 -1.29% 9,821
10/07/26 US$0.008500 -9.09% 317,881

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVFM Stock